4HPPD

The partnership, announced today (January 18) will make NITYR (nitisinone) tablets available for eligible patients in the UK with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU). A Free Goods Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence. Stuart Bell, senior vice president, Inceptua early access said: “Inceptua is proud to partner with Cycle in this Free Goods Programme to allow access to NITYR to a broader number of countries and patients. Cycle’s ethos around medicine provision aligns very closely to those of Inceptua’s, and we look forward to supporting patients with no other treatment options for these devastating diseases.” Rare genetic condition Ht-1 is a very rare genetic condition. It prevents the body from breaking down a substance called tyrosine found in food. This leads to the build-up of toxic levels of substances in the blood. If left untreated, TYR1 can damage the liver, kidneys, and the nervous system. The NHS describes AKU, or black urine disease, as a very rare inherited disorder that prevents the body fully breaking down two protein building blocks (amino acids) called tyrosine and phenylalanine. It results in a build-up of a chemical called homogentisic acid in the body. This can turn urine and parts of the body a dark color and lead to a range of health problems over time. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Cycle has an existing Free Goods Program with patients with HT-1 in India, Bangladesh, Pakistan, and Sudan. Inceptua will support Cycle through the expansion of the Free Goods Programme to include further countries where NITYR is not commercially available, or where the local healthcare system is unable to afford this medication. Countries in scope of the NITYR Free Goods Programme include Argentina, Bangladesh, Brazil, Chile, Colombia, Dominican Republic, Jordan, Mexico, Nigeria, Pakistan, Peru, Tunisia, and Turkey. Cycle says it is committed to supporting patients on the Free Goods Programme for the duration of their lifetime. Proud and humbled James Harrison, CEO of Cycle Pharmaceuticals said: “Right from the beginning of Cycle’s story in 2012, we made a commitment to provide a Free Goods Programme for rare disease patients that cannot otherwise access our medicines.  The whole Cycle team is extremely proud and humbled to be able to expand the NITYR Free Goods Programme. It really matters.” In its research, the companies found that HT-1 affects about 1 in 100,000 individuals worldwide, whilst AKU affects 1 in 250,000 to 1 million people worldwide. NITYR (nitisinone) tablets are a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase indicated for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine. NITYR has been approved for use by the FDA, Health Canada, EMA, MHRA and TGA.

PRINCETON, N.J. and CHIASSO, Switzerland, May 31, 2023 (GLOBE NEWSWIRE) -- Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration. Nitisinone Capsules are a room temperature stable, AB-rated, generic equivalent of Swedish Orphan Biovitrum's Orfadin®, and are now available in 2, 5, 10 and 20 mg capsules. Analog currently distributes the 2, 5, and 10 mg products through specialty pharmacies and now has available the 20 mg capsules for distribution. Nitisinone capsules are a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Since its use as the first-line treatment of HT-1, nitisinone has replaced liver transplantation for this rare condition. The most common side effects of nitisinone are elevated tyrosine levels, low platelet count, low white blood cell count, pink eye, white or cloudy cornea from scarring, inflammation of the cornea, light sensitivity, eye pain, inflammation of the eye lid, cataracts, low granulocytes - cells involved with immunity, nose bleeds, itching of the skin, redness and scaling of the skin, dry skin, rash and hair loss. Tanya Carro, Executive Vice President, Analog Pharma, commented, “With the approval of the 20 mg capsule, we now have a full complement of room temperature stable strengths for our generic Nitisinone. Considering that the 20 mg is the most commonly prescribed strength of Orfadin®, this will bring American patients with Hereditary Tyrosinemia type-1 (HT-1) a room temperature stable, treatment option. The addition of this new dosage form to our portfolio demonstrates our continued commitment to offering high quality cost-effective generic drugs for the treatment of rare diseases.” Analog’s Nitisinone capsules are available to eligible patients for as little as $0* per prescription. “We are pleased to announce that the FDA has now approved our 20 mg Nitisinone capsules,” - said Marc-Olivier Geinoz, CEO of Dipharma – “For the first time, American HT-1 patients will have access to 20 mg capsules which are stable at room temperature for 3 years. This is the result of the collaboration between Dipharma and our American partner Analog Pharma, which achieved this milestone ahead of time: our next milestone for this year is to extend – from 2 to 3 years - the stability at room temperature of the lower strength capsules as well. Dipharma is a pioneer in developing improved generic pharmaceutical products for rare diseases: our desire to innovate and our engagement do not stop, but every day we continue to seek new and better solutions for patients around the world”. *Terms and conditions apply About HT-1 Hereditary Tyrosinemia type-1 (HT-1) is a rare inborn error of metabolism (IEM) in which the body is unable to completely break down the amino acid tyrosine, and so harmful substances are formed, causing serious liver problems and liver cancer. HT-1 is progressive and can be fatal if untreated. For more information on HT-1, please visit https://www.dipharma.ch/science-innovation/metabolic-diseases/hereditary-tyrosinemia-type-1/. About Nitisinone INDICATION Nitisinone capsules are a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Increased levels of plasma tyrosine, eye symptoms, developmental delay and skin changes: Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosineMaintain reduction in dietary tyrosine and phenylalanine while on nitisinone.Your healthcare provider should not adjust your dosage of nitisinone in order to lower the plasma tyrosine concentration.Plasma tyrosine levels greater than 500 micromol/L may lead to the following: Ocular signs and symptoms including corneal ulcers, corneal opacities (cornea appears white or cloudy due to scarring), keratitis (inflammation of the cornea), conjunctivitis (pink eye - inflammation or infection of the outer membrane of the eye), eye pain, and light sensitivity Your healthcare provider will obtain slit-lamp examination prior to treatment, regularly during treatment and may reexamine you if you develop symptoms or if your tyrosine levels exceed 500 micromol/L. Variable degrees of intellectual disability and developmental delayPainful hyperkeratotic plaques (thickening of the skin) on the soles and palms. Maintain plasma tyrosine levels below 500 micromol/L. Changes in blood profile: You may develop leukopenia (low white blood cell count), severe thrombocytopenia (low number platelets, the cells that help the blood to clot), or both.Your healthcare provider will monitor white blood cell and platelet counts during treatment with nitisinone. ADVERSE REACTIONS The most common side effects (>1%) of nitisinone are elevated tyrosine levels, low platelet count, low white blood cell count, pink eye, white or cloudy cornea from scarring, inflammation of the cornea, light sensitivity, eye pain, inflammation of the eye lid, cataracts, low granulocytes - cells involved with immunity, nose bleeds, itching of the skin, redness and scaling of the skin, dry skin, rash and hair loss. DRUG INTERACTIONS Nitisinone can interfere with other medicines. Tell your healthcare provider about all the medicines you take. USE IN SPECIFIC POPULATIONS Pregnancy: Limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse development outcomes. Tell your healthcare provider immediately if you are pregnant or plan to get pregnant.Lactation: There are no data on the presence of nitisinone in human milk, the effects on the breastfed infant, or the effects on milk production. Tell your healthcare provider immediately if you are breastfeeding or plan to breastfeed.Pediatric Use: The safety and effectiveness of nitisinone have been established in pediatric patients for the treatment of HT-1 in combination with dietary restriction of tyrosine and phenylalanine.Geriatric Use: Clinical studies of nitisinone did not include any subjects aged 65 and over. Please read the Full Prescribing Information and Patient Instructions here. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. About Dipharma Dipharma S.A. is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence. With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach. For more information, please visit www.dipharma.ch About Analog PharmaAnalog Pharma, member of Duchesnay Pharmaceutical Group, is headquartered in Princeton, NJ, and is dedicated to producing the highest quality generic medications. Its goal is to ensure the widest possible access to high-quality medications that healthcare professionals and patients have come to rely on by producing generic versions of exceptional quality. Analog Pharma takes great pride in providing the generic medications that patients need, when they need them. For more information, please visit www.analogpharma.com About Duchesnay Pharmaceutical GroupDuchesnay Pharmaceutical Group, with its affiliated companies, is headquartered in Blainville, Quebec. The group consists of five pharmaceutical companies to meet the needs of patients in Canada, the U.S., and abroad. The companies are Duchesnay and Duchesnay USA, both dedicated to women's health; Médunik Canada and Medunik USA, which provide treatments for rare diseases; and Analog Pharma, an American generic drugs company, specializing in authorized generics and orphan drugs. From its state-of-the-art manufacturing plant, the Group can export its innovative treatments to more than 50 countries. Duchesnay, Medunik and Analog, through their proprietary research and development, and through partnerships, offer innovative treatments for a variety of medical conditions in women's health, urology, oncology as well as for rare diseases. The group of companies recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and giving back to the community through the support of various charitable organizations. For more information, please visit www.duchesnaypharmaceuticalgroup.com/en or www.analogpharma.com . Orfadin® is a registered trademark of Swedish Orphan Biovitrum/SOBI. In the United States of America Orfadin® was first approved in January 2002 for the treatment of HT-1. DISCLAIMER This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.Analog Pharma and Dipharma S.A. operates respectfully of any third party IP rights and/or regulatory exclusivities that may exists in each specific country. This press release may contain information on pharmaceuticals that are not currently approved or available in your country or region. Media contacts:DPG: Mariia Savchuk DIPHARMA: +41(0)91601170 Email: msavchuk@duchesnay.com info@dipharma.ch Phone: 1 877 833-7734 post 149 www.dipharma.ch A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d2e643-0287-49c8-b092-6cb198a388ae

SOUTH SAN FRANCISCO, California, May 22 /PRNewswire/ -- Synosia Therapeutics today announced that it has acquired a license from Syngenta to develop a potentially novel treatment for Parkinson's Disease. This is the third pharmaceutical agreement to be announced for Synosia, which started operations at the beginning of this year to develop new treatments for disorders of the central nervous system (CNS). The company now has a pipeline of seven compounds, with an option on an eighth, following previous deals with Roche and Novartis. Dr Ian Massey, Chief Executive Officer and President of Synosia Therapeutics said: "This compound is a perfect fit for our strategy of using small, smart clinical trials to rapidly establish proof-of-concept and explore the full potential of clinically-enabled drugs. "We already know a lot about this molecule and by applying innovative clinical designs, together with the latest imaging tools, we can quickly generate clinical information in new therapeutic areas," he said. The compound, called SYN-118, is a hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor, and is already approved in the US and Europe for the treatment of hereditary tyrosinemia type 1, a life-threatening metabolic disorder. The drug is marketed by Swedish Orphan International under the name Orfadin(R) (nitisinone), under license from Syngenta. Terms of the Agreement Under the terms of the agreement, Synosia will assume responsibility for the ongoing clinical development and commercialisation of SYN-118 in CNS. Contingent upon progress, Syngenta will receive milestone payments and royalties upon commercialisation. About Synosia Therapeutics Synosia Therapeutics is a privately-owned, drug development company, focused on developing new treatments for disorders of the central nervous system. Its leadership team has over 180 years of combined experience in drug development. Synosia has offices in Basel, Switzerland, and is headquartered in South San Francisco, CA. The company was spun out of EuroVentures Inc., a wholly-owned incubator of Versant Ventures, and recently changed its name from Synosis Therapeutics. Synosia Therapeutics has raised $32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit Synosia Therapeutics CONTACT: Contact Synosia Therapeutics, In Europe: Julie Walters at MediaSpeak, Tel: +44-(0)1494-753-990, Mobile +44-(0)775-3626967,julie.walters@mediaspeak.com; In US: Michele Parisi at Media Speak, Tel:+1-925-864-5028, michele.parisi@mediaspeak.com